FDA approves Myriad’s BRACAnalysis CDx for use with ovarian cancer drug

Myriad Genetics, Inc. today announced that it has received approval from the U.S. Food and Drug Administration (FDA) for BRACAnalysis CDx to be used as the only companion diagnostic in conjunction with AstraZeneca’s drug Lynparza™ (olaparib).



from The Medical News http://ift.tt/13uIr0V

Novo Nordisk gets positive CHMP opinion for expanded use of Tresiba in children with diabetes

Novo Nordisk today announced that the Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for expanded use of Tresiba® (insulin degludec) in children and adolescents aged one to 17 years with diabetes.



from The Medical News http://ift.tt/1vfGxZm

Prostaglandin analogue eye drops reduce risk of vision loss in OAG patients

Prostaglandin analogue eye drops, the most commonly prescribed treatment for glaucoma, can greatly reduce risk of vision loss in people with open angle glaucoma (OAG), one of the leading causes of blindness, according to the first placebo-controlled trial to assess their vision-preserving effect published in The Lancet.



from The Medical News http://ift.tt/13qsbh9

Hospital treatment far from home: an interview with Paul Lindsell, Managing Director at MindMetre Research

This is a generally accepted piece of received wisdom amongst clinicians and care professionals, which MindMetre validated through a series of qualitative interviews that preceded our quantitative study.



from The Medical News http://ift.tt/1zToRbn

Origins Behavioral Healthcare agrees to acquire two addiction treatment centers from Caron

A major deal in the substance abuse recovery industry will mean new treatment options for people struggling with addiction. Origins Behavioral Healthcare and Caron Treatment Centers announced today an agreement in which Origins will acquire two addiction treatment centers owned and operated by Caron: Hanley Center in West Palm Beach and Gate Lodge in Vero Beach, Fla.



from The Medical News http://ift.tt/16Gc2Gv

FDA approves AbbVie's VIEKIRA PAK for treatment of patients with GT1 HCV infection

The U.S. Food and Drug Administration has approved AbbVie's VIEKIRA PAK, an all-oral, interferon-free treatment, with or without ribavirin (RBV), for the treatment of patients with chronic genotype 1 (GT1) hepatitis C virus (HCV) infection, including those with compensated cirrhosis.



from The Medical News http://ift.tt/1AUen9E

Joerns RecoverCare introduces unique mattress coverlet system to support wound care

Joerns RecoverCare has launched ClimateCare; a unique mattress coverlet system that provides microclimate management. When used in conjunction with a pressure redistribution mattress, ClimateCare is designed to address the root causes of tissue breakdown through the management of temperature and moisture (microclimate) at the interface between the patient's skin and the therapy support surface.



from The Medical News http://ift.tt/1AuHvGr